Pacific Edge ends week on high
The company’s shares were up 5% to 84 cents on the news that its volume numbers for its cancer test increased 32% in the same quarter last year and the southern district health region is picking up its bladder tests.
Peter McIntyre, an investment advisor at Craigs Investment Partners, said Pacific Edge’s increase in test numbers was “very good” but ultimately the market is waiting for its revenue and it would be the next step for the company to accomplish.
The S&P/NZX 50 Index fell 6.5 points, or 0.06%, to 11,302.54. Turnover was on the light side at $94 million.
Although the index ended the week down 6 points, McIntyre said New Zealand’s market had been up most of the day due to the fact that news around "anything that isn't about interest rates is currently being seen as good news to the market”.
Click the button below to subscribe and will have free unlimited access for a limited time to full article and all other articles on the site.
You will also be able to comment on articles on Good Returns.
![[Weekly Wrap] KiwiSaver in play; but outcome unclear](https://goodreturns.publit.io/file/c_fill,w_300,h_200/0ad582e4-c9a3-4692-bbe2-62d928f77fd2.jpg)
